주식/증권
📉 부정적
Novo Nordisk Is Exiting a ‘Rough Patch,’ CFO Says. Earnings Prove It.
요약
The Danish drugmaker continues to rely on the success of semaglutide, branded as Wegovy for weight loss and Ozempic for diabetes.